TransEnterix Announces Sale Of Senhance Robotic Surgery System At Saitama Medical University International Medical Center In Japan
Leading Japanese Academic Medical Center is First to Bring Senhance Robot to Japan
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that the Company has sold a Senhance Robotic Surgery System to the Saitama Medical University International Medical Center located in the Saitama Prefecture in the Greater Tokyo region.
“Japan is the second largest market for medical devices as well as robotic assisted surgery devices, and has a history of driving innovation in advanced minimally invasive surgery,” said Todd M. Pope, President and CEO at TransEnterix. “We are pleased that Professor Koyama and his clinical team have seen the unique opportunity for the Senhance System to enhance laparoscopic surgery for his patients at a prestigious academic medical center like Saitama Medical University International Medical Center.”
The Senhance System was purchased in Japan under a physician import license, which allows cutting-edge medical devices to be directly purchased by Japanese physicians. The Senhance does not have broader market approval for sale in Japan.
“We have chosen to incorporate robotic assistance into our minimally invasive surgical program for the first time because of the unique clinical and financial advantages of Senhance,” said Professor Isamu Koyama, Surgeon and Director of Saitama Medical University International Medical Center. “We are excited to be able to contribute to the development of a new robotic surgery platform by utilizing this system in Japan. The Senhance brings robotic precision, enhanced vision and control with haptic feedback. The reusable instruments allow for low procedural costs, similar to traditional laparoscopy, which is critical in the Japanese healthcare system.”
About Saitama Medical University International Medical Center
Saitama Medical University International Medical Center was established in April 2007 with the objective of contributing to regional and Japanese medicine, aiming to create an internationally competitive world-class hospital. Their mission is to cover all areas of Saitama prefecture, to be dedicated in highly specialized medical service for cancer and heart disease, and to provide advanced critical and emergency medical care. The medical center is affiliated with Saitama Medical University Medical Hospital, and is one of the top ranked hospitals in Japan. Saitama Medical University International Medical Center is the first university hospital in Japan to be Joint Commission International (JCI) accredited.
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company also developed the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark and is currently under FDA 510(k) review for clearance in the United States. For more information, visit the TransEnterix website at www.transenterix.com.
This press release includes statements relating to the Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include risks associated with Japan’s physician import licensing, whether TransEnterix will receive broader Japanese regulatory clearance and whether Professor Koyama, and his clinical team, have seen the unique opportunity for the Senhance system to enhance laparoscopic surgery for his patients at a prestigious academic medical center like Saitama Medical University International Medical Center. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 6, 2017 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For TransEnterix, Inc.
Mark Klausner, +1 443-213-0501
(For EU) Conrad Harrington, +44 (0)20 3178 8914
(For US) Hannah Dunning, +1 415-618-8750